Overview

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Collaborator:
Hoffmann-La Roche
Treatments:
Erlotinib Hydrochloride